![Keith Manchester](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Keith Manchester
Direktor/Vorstandsmitglied bei
ROIVANT SCIENCES LTD.
Vermögen: 62 Mio $ am 30.06.2026
Profil
Keith S.
Manchester currently works at Roivant Sciences Ltd., as Independent Director from 2014, Roivant Sciences, Inc., as Director from 2014, Kriya Therapeutics, Inc., as Director, and QVT Financial LP, as Partner & Portfolio Manager from 2005.
Dr. Manchester also formerly worked at Resolvyx Pharmaceuticals, Inc., as Director, Arbutus Biopharma, Inc., as Director from 2014 to 2015, Myovant Sciences Ltd., as Director from 2016 to 2018, Montes Archimedes Acquisition Corp., as Independent Director, Arbutus Biopharma Corp., as Independent Director from 2015 to 2025, Applied Molecular Evolution, Inc., as Vice President-Business Development from 2002 to 2004, VCP I Inc, as Associate from 1997 to 1998, MediGene AG, as Independent Member-Supervisory Board, and Life Sciences Qvt Financial LP, as Partner & Head.
Dr. Manchester received his doctorate degree from Harvard Medical School and undergraduate degree from Harvard College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ROIVANT SCIENCES LTD. 0,24 % | 30.06.2026 | 1.748.403 ( 0,24 % ) | 62 Mio $ | 30.06.2026 |
Aktive Positionen von Keith Manchester
| Unternehmen | Position | Beginn |
|---|---|---|
| ROIVANT SCIENCES LTD. | Direktor/Vorstandsmitglied | 01.01.2014 |
QVT Financial LP
 QVT Financial LP Investment ManagersFinance QVT Financial is a global multi-strategy hedge fund manager that invests in biotech and healthcare, energy and shipping, financials and structured finance, opportunistic and litigation, and technology. | Portfolio Manager-Aktien | 01.01.2005 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Direktor/Vorstandsmitglied | 01.01.2014 |
Kriya Therapeutics, Inc.
 Kriya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing gene therapies for treatment of chronic diseases | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Keith Manchester
| Unternehmen | Position | Ende |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Direktor/Vorstandsmitglied | 24.02.2025 |
| MYOVANT SCIENCES LTD. | Direktor/Vorstandsmitglied | 20.09.2018 |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Provides biotechnology and pharmaceutical solutions | Direktor/Vorstandsmitglied | 01.03.2015 |
VCP I Inc
 VCP I Inc Investment ManagersFinance VCP invests in middle market companies located in the United States. The firm focuses on sectors such as consumer, healthcare and business & technology services. It provides financing for buyout, MBO, carve-outs and growth capital requirements and acquires both control and minority investments. It also makes follow-on investments. | Corporate Officer/Principal | 31.12.1998 |
| ROIVANT SCIENCES LTD. | Direktor/Vorstandsmitglied | - |
Ausbildung von Keith Manchester
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
47
Beziehungen ersten Grades
15
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 15 |
|---|---|
Applied Molecular Evolution, Inc.
 Applied Molecular Evolution, Inc. BiotechnologyHealth Technology Develops and manufactures proteins & genes for commercial purposes | Health Technology |
QVT Financial LP
QVT Financial LP Investment ManagersFinance QVT Financial is a global multi-strategy hedge fund manager that invests in biotech and healthcare, energy and shipping, financials and structured finance, opportunistic and litigation, and technology. | Finance |
Resolvyx Pharmaceuticals, Inc.
 Resolvyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for inflammatory diseases | Health Technology |
Arbutus Biopharma Corp.
 Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Provides biotechnology and pharmaceutical solutions | Health Technology |
Roivant Sciences Ltd.
 Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
VCP I Inc
VCP I Inc Investment ManagersFinance VCP invests in middle market companies located in the United States. The firm focuses on sectors such as consumer, healthcare and business & technology services. It provides financing for buyout, MBO, carve-outs and growth capital requirements and acquires both control and minority investments. It also makes follow-on investments. | Finance |
MediGene AG
 MediGene AG BiotechnologyHealth Technology Engages in the clinical research and development of novel drugs against cancer & autoimmune diseases with focus on personalized immunotherapies | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
 Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides women's health and prostate cancer solutions | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Life Sciences Qvt Financial LP | |
Kriya Therapeutics, Inc.
Kriya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing gene therapies for treatment of chronic diseases | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
